This is a Validated Antibody Database (VAD) review about human VLDLR, based on 4 published articles (read how Labome selects the articles), using VLDLR antibody in all methods. It is aimed to help Labome visitors find the most suited VLDLR antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
VLDLR synonym: CAMRQ1; CARMQ1; CHRMQ1; VLDL-R; VLDLRCH; very low-density lipoprotein receptor; VLDL receptor
Santa Cruz Biotechnology
mouse monoclonal (6A6) |
| In order to examine the effect of reelin derivatives on macrophage cholesterol metabolism, Santa Cruz Biotechnology VLDLR antibody (Santa Cruz Biotechnology, sc-18824) was used in ELISA on mouse samples (fig 2) and in western blot on mouse samples (fig 5). PLoS ONE (2015) ncbi |
mouse monoclonal (6A6) |
| Santa Cruz Biotechnology VLDLR antibody (santa Cruz, sc-18824) was used in western blot on human samples (fig st2). BMC Cancer (2015) ncbi |
mouse monoclonal (6A6) |
| Santa Cruz Biotechnology VLDLR antibody (Santa Cruz Biotechnology, 6A6) was used in flow cytometry on mouse samples (fig 7b). J Immunol (2014) ncbi |
mouse monoclonal |
| Santa Cruz Biotechnology VLDLR antibody (Santa Cruz Biotechnology, 6A6) was used in flow cytometry on mouse samples (fig 7b). J Immunol (2014) ncbi |
OriGene
mouse monoclonal (6A6) |
| OriGene VLDLR antibody (Origene, TA309928) was used in western blot on mouse samples (fig 5). PLoS ONE (2016) ncbi |
Articles Reviewed
- De Gonzalo Calvo D, López Vilaró L, Nasarre L, Pérez Olabarría M, Vázquez T, Escuin D, et al. Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study. BMC Cancer. 2015;15:460 pubmed publisher
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments